JP2006511620A - 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法 - Google Patents

抗ｃｄ３抗体による潰瘍性大腸炎の処置方法 Download PDF

Info

Publication number
JP2006511620A
JP2006511620A JP2005508486A JP2005508486A JP2006511620A JP 2006511620 A JP2006511620 A JP 2006511620A JP 2005508486 A JP2005508486 A JP 2005508486A JP 2005508486 A JP2005508486 A JP 2005508486A JP 2006511620 A JP2006511620 A JP 2006511620A
Authority
JP
Japan
Prior art keywords
antibody
patient
patients
visilizumab
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005508486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511620A5 (https=
Inventor
ウォルターズ，イアン
Original Assignee
プロテイン デザイン ラブス インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロテイン デザイン ラブス インコーポレイティド filed Critical プロテイン デザイン ラブス インコーポレイティド
Publication of JP2006511620A publication Critical patent/JP2006511620A/ja
Publication of JP2006511620A5 publication Critical patent/JP2006511620A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2005508486A 2002-12-05 2003-12-05 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法 Pending JP2006511620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43164902P 2002-12-05 2002-12-05
US45018303P 2003-02-25 2003-02-25
PCT/US2003/038809 WO2004052397A1 (en) 2002-12-05 2003-12-05 Methods of treatment of ulcerative colitis with anti-cd3 antibodies

Publications (2)

Publication Number Publication Date
JP2006511620A true JP2006511620A (ja) 2006-04-06
JP2006511620A5 JP2006511620A5 (https=) 2007-01-25

Family

ID=32511592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005508486A Pending JP2006511620A (ja) 2002-12-05 2003-12-05 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法

Country Status (7)

Country Link
US (1) US20040253237A1 (https=)
EP (1) EP1567192A4 (https=)
JP (1) JP2006511620A (https=)
KR (1) KR20050091713A (https=)
AU (1) AU2003298015A1 (https=)
CA (1) CA2508264A1 (https=)
WO (1) WO2004052397A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1687066T3 (da) 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
WO2007026742A1 (ja) * 2005-08-30 2007-03-08 Ajinomoto Co., Inc. 大腸デリバリー型炎症性大腸疾患治療薬
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
AU2012201443B2 (en) * 2006-06-06 2014-04-03 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN118562007A (zh) * 2019-12-19 2024-08-30 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19905012A1 (de) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Arzneimittel enthaltend Anti-CD3- und Anti-Fcgamma-R-Antikörper zur begleitenden Behandlung bei Organtransplantationen
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与

Also Published As

Publication number Publication date
KR20050091713A (ko) 2005-09-15
US20040253237A1 (en) 2004-12-16
WO2004052397A1 (en) 2004-06-24
AU2003298015A1 (en) 2004-06-30
CA2508264A1 (en) 2004-06-24
EP1567192A4 (en) 2006-02-08
EP1567192A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
JP2006511620A (ja) 抗ｃｄ３抗体による潰瘍性大腸炎の処置方法
EP3019191B1 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
US20220288199A1 (en) Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
US20230197278A1 (en) Multi-variate model for predicting cytokine release syndrome
KR102887037B1 (ko) 호중구 질환을 치료하는 방법
TWI700093B (zh) 雙重ｖ區類抗體蛋白質之用途
JPH06500229A (ja) 擬人化ｃｄｒ移植抗ｉｃａｍ―１抗体、その生産方法及びその使用
US20210040209A1 (en) Methods of treating prostate cancer with an anti- psma/cd3 antibody
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
JP2017078075A (ja) 対象の選択および治療
KR20240004451A (ko) Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법
JP2024069230A (ja) 慢性回腸嚢炎の治療のための方法
US20250059290A1 (en) Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
US20070224191A1 (en) Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
JP6430082B1 (ja) 低用量抗ｃｃｒ４抗体を用いたｈｔｌｖ−１関連脊髄症の予防または治療剤
CN120204385A (zh) 治疗系统性硬化症的方法
WO2025030110A1 (en) Cancer therapies targeting vista as monotherapy or in combination with anti-pd1 antibody to treat cancer
TW201940193A (zh) 投與ｉｌ－４ｒ拮抗劑治療鼻息肉症之方法
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
US20260041768A1 (en) Methods for treating multiple myeloma with car-t cells and bispecific antibodies
US20240158522A1 (en) Methods of Treating Ulcerative Colitis with Anti-LIGHT Antibodies
JP2025501865A (ja) 抗ｌｉｇｈｔ抗体で喘息を治療する方法
HK40110527A (zh) 伊奈利珠单抗及其在治疗或预防igg4相关疾病中的使用方法
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
WO2025198912A1 (en) Methods of treating myasthenia gravis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622